These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25546219)

  • 1. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
    Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
    Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
    Acar E; Çapa Kaya G; Durak H
    Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Makis W; McCann K; Bryanton M; McEwan AJ
    Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
    Thakral P; Sen I; Das SS; Manda D; Cb V; Malik D
    Br J Radiol; 2021 Oct; 94(1126):20210403. PubMed ID: 34357794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with
    Adnan A; Basu S
    J Nucl Med Technol; 2020 Mar; 48(1):36-39. PubMed ID: 31401619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.